Risankizumab

Drug Profile

Risankizumab

Alternative Names: ABBV 066; BI-655066; Humanised IgG1 monoclonal antibody - Boehringer Ingelheim

Latest Information Update: 15 Feb 2017

Price : $50

At a glance

  • Originator Boehringer Ingelheim
  • Developer AbbVie; Boehringer Ingelheim
  • Class Antipsoriatics; Monoclonal antibodies
  • Mechanism of Action Interleukin-23 subunit p19 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Crohn's disease
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Plaque psoriasis
  • Phase II Ankylosing spondylitis; Asthma; Crohn's disease; Psoriatic arthritis
  • Phase I Psoriasis
  • Phase Unknown Erythrodermic psoriasis; Pustular psoriasis

Most Recent Events

  • 01 Feb 2017 AbbVie initiates an open-label extension phase III trial in plaque psoriasis in USA and Canada (NCT03047395)
  • 13 Jan 2017 Investigation in Erythrodermic psoriasis in Japan (SC) before January 2016
  • 13 Jan 2017 Investigation in Pustular psoriasis in Japan (SC) before January 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top